Malaria represents one of the most serious threats to human health worldwide, and preventing and curing this parasitic disease still depends predominantly on the administration of a small number of ...
Jigang Wang et al. have made significant progress in unraveling the antimalarial mechanisms of artemisinin (ART) and its derivatives. Their latest research, published in the journal Engineering, sheds ...
For the past quarter-century, the gold standard malaria treatment has been artemisinin combination therapies (ACTs). Yet ...
Malaria is one of the most dangerous infectious diseases. The causative pathogens are microorganisms of the genus Plasmodium. A particularly dangerous form of the disease is caused by Plasmodium ...
Because of increasing resistance to current antimalarial drugs, new agents with novel mechanisms of action are needed. Plasmepsins are a family of 10 Plasmodium falciparum aspartic proteases (PMI to ...
Novartis plans to seek quick regulatory approvals from health authorities for the drug, known as GanLum, which would be the ...
The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...
Novartis has reported successful Phase III results for GanLum, a new non-artemisinin antimalarial designed to combat growing ...
Welltica+ on MSN
Breakthrough drug could protect millions from malaria
A new drug called GanLum has shown over 97% success in treating malaria, offering fresh hope as resistance to standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback